Viewing Study NCT07218003


Ignite Creation Date: 2025-12-24 @ 7:12 PM
Ignite Modification Date: 2025-12-27 @ 8:39 AM
Study NCT ID: NCT07218003
Status: RECRUITING
Last Update Posted: 2025-10-24
First Post: 2025-10-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Sponsor: Rondo Therapeutics
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module